Evidence map›Paper›PMID 41114813›Full record

ArticleAnnals of hematology2025

Diffuse Large B-cell lymphoma in a Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).

Chao Sun, Lina Zhao, Jun Xia, Kai Wang, Sujuan Zhou, Lingfeng Liu, Shudong Yang, Yongqin Cao, Zhiheng Li, Xin Zhou and 1 more

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chao Sun *Department of Hematology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Lina Zhao *Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Jun XiaDepartment of Hematology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Kai WangAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Sujuan ZhouAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Lingfeng LiuAdvanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
Shudong YangDepartment of Pathology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Yongqin CaoDepartment of Hematology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Zhiheng LiDepartment of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Xin ZhouDepartment of Hematology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China. 13358111962@qq.com.
Sheng XiaoDepartment of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, 02115, USA. xiaosheng2023@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS genes are among the most mutated genes in human cancers, with KRAS G12C now being targetable by the specific inhibitor Sotorasib. Ras-associated autoimmune leukoproliferative disorder (RALD) is a rare condition characterized by somatic RAS mutations and hyperactive MAPK signaling. RALD typically affects pediatric patients and is generally considered a benign condition. We report a unique case of RALD in a 76-year-old patient, who is the oldest individual with this disorder to date. This patient also developed lymphoma, marking the fourth known case of malignancy associated with RALD. Additionally, a novel fusion, RHOH::PDCD1LG2 (PD-L2), was identified in the lymphoma, alongside the KRAS mutation. This fusion likely contributes to tumorigenesis through immune evasion.

Indexed as

Autoimmune DiseasesAutoimmune Lymphoproliferative SyndromeLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins p21(ras)AgedHumansMaleMutationProto-Oncogene Proteins p21(ras)KRASPD-L2RALDRHOH

Identifiers

PMID41114813
PMCPMC12672693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.